Guy Goodwin

Guy completed his medical degree and DPhil in physiology at the University of Oxford and, following training in psychiatry, worked as Clinical Scientist at the MRC Brain Metabolism Unit in Edinburgh for 10 years. He moved back to Oxford as head of the department of psychiatry and subsequently as a senior research fellow. His work has always included care of outpatients along with a primary commitment to research. He is a Fellow of the American College of Neuropsychopharmacology, and has previously held the position of President of the British Association for Psychopharmacology, President of the European College of Neuropsychopharmacology (ECNP), and Senior Investigator on the faculty of UK National Institute for Health Research (NIHR). He is a Thomson Reuters highly cited researcher (top 1% in field).

His research interests have been focused on the treatment of mood disorder and, increasingly, the potential to improve treatment using new technology and new drugs, notably psychedelics. He was part of the team that developed COMPASS Pathways’ phase IIb clinical trial and acted initially as its coordinating principal investigator.